Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer

BACKGROUND: Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This study investigates benefits and harms of screening strategi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Natl Cancer Inst
Prif Awduron: Heijnsdijk, Eveline A M, Gulati, Roman, Tsodikov, Alex, Lange, Jane M, Mariotto, Angela B, Vickers, Andrew J, Carlsson, Sigrid V, Etzioni, Ruth
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566340/
https://ncbi.nlm.nih.gov/pubmed/32067047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djaa001
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg